CJC-1295 (No DAC) / GHRP-6Explore study findings
What a stroke-model experiment tells us about identifying a peptide's partner
2 numbered sourcesSource years 2024, 2026
Peptides are short chains of amino acids joined by peptide bonds. Some activate receptors that affect how cells respond to signals or injury. CJC-1295 (No DAC) / GHRP-6 pairs the label commonly used for modified growth hormone–releasing factor (1–29) with GHRP-6, a synthetic six-residue agonist of the ghrelin receptor. Can a study pairing GHRP-6 with a different molecule answer questions about this one? [1, 2]
No recent primary study of the exact no-DAC combination was identified. A June 2026 rat study instead combined GHRP-6 with epidermal growth factor, or EGF, after experimentally interrupting blood flow to part of the brain. The investigators compared proteins in vulnerable tissue around the injury with proteins in control animals. They found changes at two sampling times, including in groups of proteins associated with neurotransmitter transport and the cellular response to stress. [2]
In that experiment the EGF–GHRP-6 group was compared with injured rats that received a control solution and with sham-operated rats. The design estimated what changed under the two-peptide exposure. Separate groups exposed to just EGF or just GHRP-6 would be needed to assign those protein changes to either one independently. Such groups could also help evaluate an interaction using a defined expectation for the individual responses. [2]
The finding is about a rat stroke model, a particular combination and a set of tissue measurements. EGF is a different molecule from the no-DAC GHRH analogue. The recent experiment provides an example of why naming the partner and the comparison groups matters when interpreting combination research. It leaves the named catalog mixture untested. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
